BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 10063676)

  • 1. Candidate bacterial conditions.
    Cohen ML
    Bull World Health Organ; 1998; 76 Suppl 2(Suppl 2):61-3. PubMed ID: 10063676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus and Haemophilus influenzae type b vaccine.
    Black S; Greenberg DP
    Expert Rev Vaccines; 2005 Dec; 4(6):793-805. PubMed ID: 16372875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
    Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
    Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Eradication of contagious diseases].
    Zikmund V
    Epidemiol Mikrobiol Imunol; 1999 Feb; 48(1):3-7. PubMed ID: 11038669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of two Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccines (PRP-T) given with diphtheria-tetanus-pertussis vaccine to young Papua New Guinean children.
    Lehmann D; Kakazo M; Saleu G; Taime J; Javati A; Namuigi P; Alpers MP; Wegmüller B; Zellmeyer M; Fürer E; Que JU; Herzog C
    P N G Med J; 2001; 44(1-2):6-16. PubMed ID: 12418673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered.
    Daum RS; Zenko CE; Given GZ; Ballanco GA; Parikh H; Germino K
    J Infect Dis; 2001 Nov; 184(10):1293-9. PubMed ID: 11679918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Existing antibacterial vaccines.
    Mendoza N; Ravanfar P; Satyaprakash A; Pillai S; Creed R
    Dermatol Ther; 2009; 22(2):129-42. PubMed ID: 19335724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine.
    Omeñaca F; Garcia-Sicilia J; García-Corbeira P; Boceta R; Torres V
    Pediatrics; 2007 Jan; 119(1):e179-85. PubMed ID: 17145903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
    Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
    Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines.
    Slack MH; Schapira D; Thwaites RJ; Burrage M; Southern J; Andrews N; Borrow R; Goldblatt D; Miller E
    J Infect Dis; 2001 Dec; 184(12):1617-20. PubMed ID: 11740740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunological response of Thai infants to haemophilus influenzae type B polysaccharide-tetanus conjugate vaccine co-administered in the same syringe with locally produced diphtheria-tetanus-pertussis vaccine.
    Kerdpanich A; Hutagalung Y; Watanaveeradej V; Bock HL; Steinhoffmd M
    J Med Assoc Thai; 2007 Jul; 90(7):1330-6. PubMed ID: 17710973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Dylag AM; Shah SI
    Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines.
    Huebner RE; Nicol M; Mothupi R; Käyhty H; Mbelle N; Khomo E; Klugman KP
    Vaccine; 2004 Dec; 23(6):802-6. PubMed ID: 15542205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of neonatal tetanus will save 1 million newborns annually.
    Soz Praventivmed; 1996; 41(4):262-3. PubMed ID: 8806160
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
    Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis.
    de Voer RM; van der Klis FR; Nooitgedagt JE; Versteegh FG; van Huisseling JC; van Rooijen DM; Sanders EA; Berbers GA
    Clin Infect Dis; 2009 Jul; 49(1):58-64. PubMed ID: 19480581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Eradication of infectious diseases and vaccination].
    Bégué P
    Bull Acad Natl Med; 2001; 185(4):777-84. PubMed ID: 11503363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.